Skip to Content
Merck
All Photos(1)

Documents

1285873

USP

Fluticasone propionate

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(6α,11β,16α,17α)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid S-(fluoromethyl) ester

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C25H31F3O5S
CAS Number:
Molecular Weight:
500.57
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

fluticasone

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF

InChI

1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1

InChI key

WMWTYOKRWGGJOA-CENSZEJFSA-N

Gene Information

human ... NR3C1(2908)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluticasone propionate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Fluticasone Propionate and Salmeterol Inhalation Aerosol®
  • Fluticasone Propionate and Salmeterol Inhalation Powder
  • Fluticasone Propionate Cream
  • Fluticasone Propionate Inhalation Aerosol®
  • Fluticasone Propionate Inhalation Powder
  • Fluticasone Propionate Lotion

Biochem/physiol Actions

Fluticasone propionate is a second generation glucocorticoid. Used as an anti-inflammatory agent for asthma. Shown to enhance eosinophil apoptosis in a concentration-dependent manner via the glucocorticoid receptor.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Legal Information

Aerosol is a registered trademark of Cytec Technology Corp.

related product

Product No.
Description
Pricing

Pictograms

Health hazard

Signal Word

Warning

Hazard Statements

Hazard Classifications

Repr. 2 - STOT RE 2

Target Organs

Endocrine system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Wei Liu et al.
Experimental and therapeutic medicine, 8(4), 1313-1317 (2014-09-05)
This study was designed to determine the expression of serum and sputum surfactant protein D (SP-D) in chronic obstructive pulmonary disease (COPD) and its association with treatment response. Sixty-five treatment-naive patients with COPD and 26 normal control subjects were recruited
M Berger et al.
Allergy, 70(3), 257-264 (2014-11-11)
House dust contains mite allergens as well as bacterial products such as lipopolysaccharide (LPS). Asthma exacerbations are associated with the level of exposure to allergens and LPS. LPS can potentiate allergen effects in steroid-naïve patients. Long-acting β2-agonists (LABA) were shown
T Welte et al.
International journal of clinical practice, 69(3), 336-349 (2014-11-05)
Chronic obstructive pulmonary disease (COPD) is usually a progressive condition. Undiagnosed early-stage disease, particularly in symptomatic patients, is likely to become more severe with time. Hence, prevention or reduction in disease progression is highly relevant. We evaluated the published data
Brian L Le et al.
Research square (2021-04-07)
The novel SARS-CoV-2 virus emerged in December 2019 and has few effective treatments. We applied a computational drug repositioning pipeline to SARS-CoV-2 differential gene expression signatures derived from publicly available data. We utilized three independent published studies to acquire or
Juliet M Foster et al.
The Journal of allergy and clinical immunology, 134(6), 1260-1268 (2014-07-27)
Poor adherence contributes to uncontrolled asthma. Pragmatic adherence interventions for primary care settings are lacking. To test the effectiveness of 2 brief general practitioner (GP)-delivered interventions for improving adherence and asthma control. In a 6-month cluster randomized 2 × 2

Articles

Learn how the Purospher® STAR RP-18e Hibar® HPLC column meets the system suitability criteria outlined in the USP monograph for the fluticasone propionate assay.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service